3189 results for «806»

Filter By

3189 results

TAVI in small annulus - LIVE Case

11 Dec 2025 – From GulfPCR-GIM 2025

A 65-year-old female with obesity, diabetes mellitus, a history of stroke, atrial fibrillation, and RBBB on ECG, presented with symptomatic aortic stenosis and two-vessel coronary disease (OM and LAD, QFR: 0.70). Echocardiography and CT showed normal LV function (55%), a small annulus (370 mm²), and a...

TAVI in small annulus - LIVE Case

Iatrogenic atrial septum defect closure: a necessary procedure?

18 Nov 2025 – From PCR London Valves 2025

This session addresses the clinical considerations surrounding iatrogenic atrial septal defects (ASDs) resulting from transseptal procedures. It covers prevention of residual defects, diagnostic evaluation, criteria for closure, procedural timing, and management strategies for related complications, supported by illustrative clinical cases demonstrating decision-making nuances.

TAVI complications - Part 5

18 Nov 2025 – From PCR London Valves 2025

This session highlights acute and urgent complications following TAVI implantation, including myocardial infarction, cardiac arrest, and challenging catheterization scenarios. It provides detailed case analyses illustrating the limits of TAVI procedures and the critical importance of prompt recognition and intervention in adverse events, enhancing clinician preparedness for...

Getting ready for tricuspid TEER: key steps in building a successful programme

14 Feb 2026 – From PCR Tokyo Valves 2026

Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.

Getting ready for tricuspid TEER: key steps in building a successful programme

Patient selection for tricuspid TEER in 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...

Patient selection for tricuspid TEER in 2026

A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death

18 May 2021

The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative...

A new meta-analysis supports elective revascularization and medical therapy for reducing cardiac death

EuroPCR 2025 – Meta-Analysis of Individual Patient Data from the PROTECTED TAVR and BHF PROTECT-TAVI Trials

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...

EuroPCR 2025 – Meta-Analysis of Individual Patient Data from the PROTECTED TAVR and BHF PROTECT-TAVI Trials

IVUS-guided versus angiography-guided PCI in unprotected left main coronary artery disease – The OPTIMAL trial

31 Mar 2026

Ali Nazmi Calik provides his take on the results of the OPTIMAL trial presented by Luca Testa at ACC.26 in New Orleans.

Author

Ali Nazmi Calik
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in unprotected left main coronary artery disease – The OPTIMAL trial

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
Didn’t find what you were looking for?